Raymond James cuts Verisk Analytics stock price target on valuation

Raymond James cut Verisk Analytics' price target to $230 from $260 but kept a Strong Buy rating, while raising its 2027 operating EPS estimate to $8.35 and initiating 2028 EPS at $9.10. Verisk also executed $1.5 billion of accelerated share repurchases plus $126 million of open-market buybacks in Q1 2026, reinforcing confidence in free cash flow and keeping leverage within its 2-3x target range. Recent Q1 2026 results beat expectations with EPS of $1.82 versus $1.74 and revenue of $783 million versus $771.51 million, while new AI connector launches add a positive strategic angle.

Analysis

The market is treating this as a simple quality/value reset, but the bigger signal is that management is effectively saying the equity is cheap enough to lever up against. That matters because buybacks at this scale are most powerful when the underlying earnings stream is subscription-like and low cyclicality; it shortens the path to per-share compounding even if organic growth only stays mid-single digits. The added debt is not the story by itself — the story is that the company is intentionally re-rating itself from a pure earnings compounder into a capital returns compounder, which should support multiple stability once the market stops penalizing leverage mechanically.

The second-order winner is likely not just VRSK shareholders but also any adjacent insurance workflow vendors that can tie into its data distribution rails. The AI connector initiative is strategically important because it can raise switching costs without requiring a major monetization breakthrough; embedding into underwriting and claims workflows makes the product more sticky and could reduce churn over the next 12-24 months. That said, the near-term AI narrative is more about option value than revenue acceleration, so investors should not underwrite a meaningful top-line contribution until insurers move from pilots to production at scale.

The main risk is that the current valuation floor may prove illusory if the market keeps focusing on leverage while the multiple stays compressed. If rates back up or credit spreads widen, the buyback accretion story loses appeal because equity support weakens and debt service becomes a more visible constraint. The other catalyst path is earnings durability: if 2027 guidance continues to step up while leverage trends toward the low end of the target range, the stock can re-rate sharply over 6-9 months; if growth stalls, the stock could remain stuck near bookend valuation despite aggressive repurchases.

Consensus seems to be missing that the current setup is asymmetric because the company has already signaled willingness to pull forward per-share value creation with repurchases, which reduces downside from purely operational disappointment. The contrarian question is whether the stock deserves a quality premium at all if the next leg of EPS growth is increasingly financial-engineering driven rather than organically accelerating. That makes this less of a 'cheap compounder' and more of a 'controlled leverage + buyback execution' story, which is attractive only as long as cash conversion and renewal economics stay intact.

Key Decisions for Investors

• Go long VRSK over a 6-12 month horizon; buy on weakness toward the low-$160s with a target back to the low-$200s if 2027 EPS revisions continue and leverage trends down. Risk/reward is favorable because buyback support should dampen drawdowns, but the thesis fails if financing costs rise materially or organic growth decelerates.
• Pair trade: long VRSK / short a slower, more cyclical insurance-services or data-services peer with less capital return support. The goal is to isolate the per-share compounding + sticky-revenue factor while reducing market beta; expect this to work best over 2-4 quarters as estimates are revised.
• Use call spreads rather than outright equity if entering before the next earnings reset: 6-9 month VRSK call spreads centered above current trading levels. This captures multiple expansion if the market accepts the buyback/leverage trade-off, while capping downside if the stock remains rangebound.
• Avoid shorting VRSK outright despite the compressed multiple; the asymmetric downside is limited by repurchase demand and recurring revenue visibility. Short interest would only be attractive if leverage drifts above target or if the company signals a pause in capital returns.